The COVID-19 vaccine candidates developed by Moderna Inc. and BioNTech and Pfizer Inc. will require strict standards for cooling, and that may hinder how they are distributed to the hundreds of millions of Americans who expect to receive them. Shares of Modern MRNA, -3.54% were 3.6% lower in trading on …
Read More »Pfizer vaccine on track for regulatory review in October
Investors applaud when two coronavirus vaccine candidates report T-cell responses, but findings are still at an early stage
At least two experimental COVID-19 vaccines produced a T-cell response in participants in early-stage clinical trials, which may indicate a longer-lasting form of immunity than an antibody response. BioNTech BNTX, + 3.46% and Pfizer Inc. PFE, + 0.69% It said early Monday morning that an ongoing early-stage clinical trial for …
Read More »UK signs agreements with BioNTech, Pfizer and Valneva for COVID-19 vaccines
The UK government said on Monday it has secured early access to 90 million doses of vaccines from two potential COVID-19 vaccines developed by a partnership between Germany’s BioNTech and US drug maker Pfizer, as well as one by the group. French Valneva. The business ministry said it had signed …
Read More »